Myovant Agrees To Be Acquired By Sumitomo Pharma Unit In $1.7B Deal As Japanese Company Sweetens Bid
October 24, 2:37 AM
Myovant Sciences, Inc. (NYSE: MYOV) announced late Sunday a deal to be acquired by Japanese pharmaceutical company Sumitomo Pharma Co., Ltd's (OTC: DNPUF) unit Sumitovant Biopharma.
AbbVie Announces RINVOQ (Upadacitinib) Receives Sixth U.S. FDA Approval
October 21, 5:00 PM
AbbVie (NYSE:ABBV) today announces that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of adults with active
Accelerate Diagnostics Says Has Been In Recent Discussions With FDA Regarding Accelerate Arc System, Related BC Kit
October 21, 4:09 PM
On October 21, 2022, Accelerate Diagnostics, Inc. (the “Company”) announced it has been in recent discussions with the U.S. Food and Drug Administration (“FDA”) regarding its Accelerate Arc
Analyst Downgrades Immunic After Lack of Details Drive Uncertainty
October 21, 3:14 PM
SVB Leerink has downgraded Immunic Inc (NASDAQ:IMUX) to Market Perform from Outperform following disappointing initial data from the highly anticipated Phase 1b proof-of-concept…
Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline
October 21, 1:35 PM
SVB Leerink downgraded Zymeworks Inc (NASDAQ:ZYME) to Market Perform with a price target of $8, down from $19 following the recent divestiture of…
Histogen Receives Decision To Grant European Patent Titled ‘CASPASE INHIBITORS AND METHODS OF USE THEREOF (FOR THE TREATMENT OF VARIOUS DISEASES)’
October 21, 12:35 PM
https://register.epo.org/application?number=EP20716287
Children’s Hospitals Strained After Climbing Cases In Respiratory Illnesses In Kids
October 21, 12:10 PM
Physicians are reporting a sharp increase in cases of the respiratory syncytial virus (RSV), creating capacity issues in several children's hospitals in the U.S. before the typically busier winter months.
GE Healthcare And Accuray Collaborate To Expand Access, Advance The Practice Of Precision Radiation Therapy
October 21, 12:02 PM
Collaboration places emphasis on personalized medicine; brings together key precision diagnostic and treatment delivery tools aimed at creating shorter, more comfortable and more effective treatments for
Sermonix Pharmaceuticals Shares Additional Findings From Its Evaluation Of Lasofoxifene In ESR1 Mutations Phase 2 Study At The 4th Annual Congress Of The ISLB NOTE: Sermonix Licensed Lasofoxifene Globally From Ligand Pharmaceuticals
October 21, 10:09 AM
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today shared additional